Cerus Corp.

Cerus Corp.

Cerus Corp.

Overview
Date Founded

1991

Headquarters

2550 Stanwell Drive, Concord, CA, 94520, USA

Type of Company

Public

Employees (Worldwide)

215

Industries

Medical Products & Equipment
Hospitals & Patient Services
Appliances & Electronics
Industrial Machinery & Manufacturing
Computer Software

Company Description

Cerus Corp. engages in the research, development, and manufacture of biomedical and surgical products. It produces blood system for platelets and plasma. It markets its products under the INTERCEPT brand. The company was founded by Laurence M. Corash and John E. Hearst on September 19, 1991 and is headquartered in Concord, CA.

Website
Contact Data
Trying to get in touch with decision makers at Cerus Corp.? Subscribe today to access their professional contact information.
Executives & Employees

President & Chief Executive Officer

Chief Financial Officer & Vice President-Finance

Vice President, Finance & Chief Financial Officer

Chief Legal Officer & General Counsel

Chief Commercial Officer

Chief Scientific Officer

Vice President, Legal Affairs & Chief Legal Officer

Chief Medical Officer

Senior Vice President, Regulatory Affairs & Quality

Vice President, Development

Board of Directors

President & Chief Operating Officer at Jazz Pharmaceuticals Plc

Chief Executive Officer & Director at eBioscience, Inc.

President & Chief Executive Officer at Cerus Corp.

Former Senior Vice President-Strategy & Business Development at Baxter International, Inc.

Paths to Cerus Corp.
Potential Connections via
Relationship Science
You
Cerus Corp.
Owners & Shareholders
Details Hidden

Baker Bros. Advisors (BBA) primarily invests client assets in public securities of life sciences and related healthcare companies. These securities include, but aren't necessarily limited to: equity securities, including exchange-listed and over-the-counter securities; warrants; corporate debt securities, including convertible bonds; options contracts on securities; and money market funds. BBA focuses on public securities, but may, from time to time, recommend investments in private companies, life sciences and related healthcare intellectual property, royalty streams or other non-public investment opportunities. The firm adheres to a fundamentally-driven approach to life sciences investing. They typically take large, concentrated positions in the securities of life sciences companies with the potential for significant value creation over the long-term.

Details Hidden

Elk Creek Partners specialize in making growth-oriented investments in publicly-traded stocks of small- and medium-sized companies. The firm offers investment advisory services for specific strategies, including Small-Cap Growth, Mid-Cap Growth and SMID-Cap Growth. Elk Creek Partners works with clients to establish investment objectives based on their unique circumstances. The key elements of the firm's investment approach are growth company identification, fundamental research, valuation analysis, and portfolio construction.The firm's Small-Cap Growth strategy is based on a fundamental, stock-by-stock approach. The portfolio is concentrated in stocks purchased with a market-cap generally of $500 million to $5 billion and with portfolio characteristics similar to the Russell 2000 Growth Index. They target companies with sustained growth and which have products and/or services that are market-share takers.Elk Creek's SMID-Cap Growth strategy is a direct extension of the Small-Cap strategy. The SMID Cap Growth strategy concentrates in stocks with a market-cap of $1 billion to $10 billion and with portfolio characteristics similar to the Russell 2500 Growth Index. The process implemented in the SMID-Cap strategy is the same as the Small-Cap strategy in both buying and selling individual stocks.The firm's Mid-Cap Growth strategy is a direct extension of the Small- and SMID-Cap Growth strategies. The Mid-Cap Growth strategy concentrates in stocks with a market-cap of $2 billion to $12 billion and with portfolio characteristics similar to the Russell Mid-Cap Growth Index. The process implemented in the Mid-Cap strategy is the same as the Small-Cap strategy in both buying and selling individual stocks. ^

Details Hidden

ARK Investment Management is a registered investment adviser and privately held investment firm, specializing in thematic investing. The firm is rooted in over thirty years of experience in identifying and investing in disruptive innovations that enable outsized growth as industries transform. Through its open source research process, ARK is able to identify companies that it believes are leading and benefiting from disruptive cross-sector forces and changing how the world works.

Recent Transactions
Details Hidden

Cerus Corp. issued Common Stock

Details Hidden

Cerus Corp. issued Common Stock

Details Hidden

Cerus Corp. issued Common Stock

Insider Transactions
Details Hidden
Details Hidden
Details Hidden
Transaction Advisors
Legal Advisor

Advised onCerus Corp. issued Common Stock

Auditor

Advised onCerus Corp. issued Common Stock

Underwriter

Advised onCerus Corp. issued Common Stock

Legal Advisor

Advised onCerus Corp. issued Common Stock

Managing Director, Initial Public Offerings

Advised onCerus Corp. issued Common Stock

Legal Advisor

Advised onCerus Corp. issued Common Stock

Advisors & Consultants
Legal Advisor

Partner at Cooley LLP

Legal Advisor

Partner at Cooley LLP

Advisor

Former Director-DAPER Investment Fund at Stanford University

Clients

The humanitarian mission of the American Red Cross connects us to people and communities across the nation and around the world. The common bonds of humanity and compassion unite us together, not just in the face of emergencies and disasters, but in helping our neighbors every day. Since being founded by Clara Barton in 1881, the Red Cross has been a consistent lifeline for people when they need us the most. The depth and breadth of our services – whenever and wherever they're called for – is unmatched by any organization in the world.

Grifols SA is a vertically integrated global producer of plasma derivatives. Its activities include sourcing raw material, manufacturing various plasma derivative products and selling and distributing final products to healthcare providers. The company operates through the following segments: Bioscience, Hospital, Diagnostic and Raw Materials. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic Segment includes the marketing of diagnostic testing equipment, reagents, and other equipment. The Raw Materials Segment includes the sale of intermediate biological products and the rendering of manufacturing services to third party companies. Grifols was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.

Key Stats and Financials As of 2017
Market Capitalization
$967M
Total Enterprise Value
$335M
Earnings Per Share
$-0.56
Revenue
$51.3M
EBITDAMargin
-108.56%
Enterprise Value Sales
6.52x
TEVNet Income
-5.53x
Debt TEV
0.09x
Net Profit
$-60.6M
EBITDA
$-55.7M
Total Equity
$38.9M
Total Debt
$29.8M
Three Year Compounded Annual Growth Rate Of Revenue
12.12%
Five Year Compounded Annual Growth Rate Of Revenue
6.89%
Investors
Details Hidden

President at Capella Photonics, Inc.

Details Hidden

Owner at Sochet & Co., Inc.

Suppliers
Nova Biomedical Corp. Medical Products & Equipment | Waltham, MA

Nova Biomedical Corp. develops and manufactures blood analyzers. Its products include automated chemistry analyzers for analysis of nutrients, metabolites, and gases in cell culture and fermentation. The company was founded in 1976 by Robert L. Coleman and is headquartered in Waltham, MA.

Fresenius SE & Co. KGaA Medical Products & Equipment | Bad Homburg, HE

Fresenius SE & Co. KGaA is a global healthcare group, which engages in the provision of products, and services for dialysis, hospitals, and outpatient medical care. It operates through the following business segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, Fresenius Vamed, and Corporate & Other. The Fresenius Medical Care segment is comprised of dialysis products, and healthcare services. The Fresenius Kabi segment provides intravenous drugs, clinical nutrition, infusion therapy, medical devices, and transfusion technology. The Fresenius Helios is the hospital operations. The Fresenius Vamed is consist of projects, and services for hospitals and other healthcare facilities. The Corporate & Other segment engages in the holding activities. The company was founded by Eduard Fresenius in October 1912 and is headquartered in Bad Homburg, Germany.

Haemonetics Corporation Medical Support Services | BRAINTREE, MA

Haemonetics Corp. is a healthcare company, which engages in the development and distribution of hematology products and solutions. It operates through the following geographical segments: Japan, EMEA (Europe, the Middle East, and Africa), North America Plasma, and All Other. Its products include surgical and diagnostic devices, blood and plasma center devices, blood center software, hospital software, and plasma center software. The company was founded by Allen Latham, Jr. in 1971 and is headquartered in Braintree, MA.

Competitors
Grifols SA Pharmaceuticals - Barcelona, CT

Grifols SA is a vertically integrated global producer of plasma derivatives. Its activities include sourcing raw material, manufacturing various plasma derivative products and selling and distributing final products to healthcare providers. The company operates through the following segments: Bioscience, Hospital, Diagnostic and Raw Materials. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic Segment includes the marketing of diagnostic testing equipment, reagents, and other equipment. The Raw Materials Segment includes the sale of intermediate biological products and the rendering of manufacturing services to third party companies. Grifols was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.

Terumo Corp. Industrial Machinery & Manufacturing - Tokyo, TY

Terumo Corp. engages in the manufacturing and sale of medical products and equipment. It operates through the following segments: General Hospital, Cardiac & Vascular, and Blood Management. The General Hospital segment produces, supplies, leases, and sells hospital equipment, pharmaceutical, home medical treatment, and peritoneal dialysis and diabetes-related products. The Cardiac & Vascular segment imports and merchandises catheter and cardiovascular systems products. The Blood Management segment manufactures and sells blood transfusion products such as blood bags and automated blood component processing devices. The company was founded by Shibasaburo Kitasato on September 17, 1921 and is headquartered in Tokyo, Japan

Kedrion S.p.A. Pharmaceuticals - Barga, LU

Kedrion SpA develops and markets biopharmaceutical products. It operates as a biopharmaceutical company which specializes in the development, production, and distribution of plasma-derived products. The firm collects and fractionates blood plasma to produce and distribute plasma-derived therapeutic products for use in treating serious diseases, disorders and conditions such as hemophilia and immune system deficiencies. It serves medical and scientific, and institutional patient communities worldwide. The company was founded in 2001 and is headquartered in Barga, Italy.